| Item Type | Name |
|
Concept
|
Renal Insufficiency, Chronic
|
|
Academic Article
|
Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease.
|
|
Academic Article
|
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
|
|
Academic Article
|
Uncertainty in the treatment of anemia in chronic kidney disease.
|
|
Academic Article
|
Correction of anemia with epoetin alfa in chronic kidney disease.
|
|
Academic Article
|
The target hemoglobin in patients with chronic kidney disease.
|
|
Academic Article
|
Anemia of chronic kidney disease: CHOIR and the FDA.
|
|
Academic Article
|
Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
|
|
Academic Article
|
Does correction of anemia slow the progression of chronic kidney disease?
|
|
Academic Article
|
Anemia of chronic kidney disease.
|
|
Academic Article
|
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease.
|
|
Academic Article
|
Iron deficiency in non-dialysis chronic kidney disease.
|
|
Academic Article
|
Hemoglobin target in chronic kidney disease: a pediatric perspective.
|
|
Academic Article
|
Does treatment with calcitriol improve survival in predialysis patients with chronic kidney disease?
|
|
Academic Article
|
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.
|
|
Academic Article
|
Role of vitamin D in chronic kidney disease.
|
|
Academic Article
|
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study.
|
|
Academic Article
|
Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
|
|
Academic Article
|
Anemia in chronic kidney disease: new advances.
|
|
Academic Article
|
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
|
|
Academic Article
|
Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study.
|
|
Academic Article
|
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
|
|
Academic Article
|
Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents.
|
|
Academic Article
|
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
|
|
Academic Article
|
Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?
|
|
Academic Article
|
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
|
|
Academic Article
|
Chronic kidney disease in the Arab world: a call for action.
|
|
Academic Article
|
Metabolic syndrome and chronic kidney disease.
|
|
Academic Article
|
Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study.
|
|
Academic Article
|
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
|
|
Academic Article
|
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.
|
|
Academic Article
|
Predictors of renal replacement therapy and mortality in children with chronic kidney disease.
|
|
Academic Article
|
Cause of Death in Patients With Diabetic CKD Enrolled in the?Trial to Reduce Cardiovascular Events With Aranesp Therapy?(TREAT).
|
|
Academic Article
|
Prevalence of Hyperparathyroidism, Mineral and Bone Disorders in Children with Advanced Chronic Kidney Disease.
|
|
Academic Article
|
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD.
|
|
Academic Article
|
BP in Dialysis: Results of a Pilot Study.
|
|
Academic Article
|
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
|
|
Academic Article
|
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
|
Academic Article
|
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
|
|
Academic Article
|
Occupational risk factors for chronic kidney disease in Andhra Pradesh: 'Uddanam Nephropathy'.
|
|
Academic Article
|
Multiparametric Cardiac Magnetic Resonance for Chronic Kidney Disease: Mapping the Footprints of a "Silent Killer"?
|
|
Academic Article
|
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
|
|
Academic Article
|
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
|
|
Academic Article
|
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
|
|
Academic Article
|
The ASCEND-ND trial: study design and participant characteristics.
|
|
Academic Article
|
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
|
|
Academic Article
|
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO.
|
|
Academic Article
|
Empagliflozin in Patients with Chronic Kidney Disease.
|
|
Academic Article
|
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials.
|
|
Academic Article
|
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
|
|
Academic Article
|
The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease.
|
|
Academic Article
|
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
|
|
Academic Article
|
Introduction: A Multi-Pronged Approach to CKD Associated With Type 2 Diabetes.
|